|
1
|
Baxter RC: Insulin-like growth factor
(IGF)-binding proteins: Interactions with IGFs and intrinsic
bioactivities. Am J Physiol Endocrinol Metab. 278:E967–E976. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rajaram S, Baylink DJ and Mohan S:
Insulin-like growth factor-binding proteins in serum and other
biological fluids: Regulation and functions. Endocr Rev.
18:801–831. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bach LA: IGF-binding proteins. J Mol
Endocrinol. 61:T11–T28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baxter RC: IGF binding proteins in cancer:
Mechanistic and clinical insights. Nat Rev Cancer. 14:329–341.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu H and Rohan T: Role of the insulin-like
growth factor family in cancer development and progression. J Natl
Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Russo VC, Azar WJ, Yau SW, Sabin MA and
Werther GA: IGFBP-2: The dark horse in metabolism and cancer.
Cytokine Growth Factor Rev. 26:329–346. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeng L, Perks CM and Holly JM:
IGFBP-2/PTEN: A critical interaction for tumours and for general
physiology? Growth Horm IGF Res. 25:103–107. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chua CY, Liu Y, Granberg KJ, Hu L,
Haapasalo H, Annala MJ, Cogdell DE, Verploegen M, Moore LM, Fuller
GN, et al: IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Oncogene. 35:738–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua
CY, Phillips LM, Ren H, Fleming JB, Wang H, et al: IGFBP2 activates
the NF-κB pathway to Drive epithelial-mesenchymal transition and
invasive character in pancreatic ductal adenocarcinoma. Cancer Res.
76:6543–6554. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fuller GN, Rhee CH, Hess KR, Caskey LS,
Wang R, Bruner JM, Yung WK and Zhang W: Reactivation of
insulin-like growth factor binding protein 2 expression in
glioblastoma multiforme: A revelation by parallel gene expression
profiling. Cancer Res. 59:4228–4232. 1999.PubMed/NCBI
|
|
11
|
McDonald KL, O'Sullivan MG, Parkinson JF,
Shaw JM, Payne CA, Brewer JM, Young L, Reader DJ, Wheeler HT, Cook
RJ, et al: IQGAP1 and IGFBP2: Valuable biomarkers for determining
prognosis in glioma patients. J Neuropathol Exp Neurol. 66:405–417.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li
G, Qiu X, Jiang T, Zhang W and Song SW: Plasma IGFBP-2 levels
predict clinical outcomes of patients with high-grade gliomas.
Neuro Oncol. 11:468–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dunlap SM, Celestino J, Wang H, Jiang R,
Holland EC, Fuller GN and Zhang W: Insulin-like growth factor
binding protein 2 promotes glioma development and progression. Proc
Natl Acad Sci USA. 104:11736–11741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Wang H, Shen W, Huang H, Hu L,
Ramdas L, Zhou YH, Liao WS, Fuller GN and Zhang W: Insulin-like
growth factor binding protein 2 enhances glioblastoma invasion by
activating invasion-enhancing genes. Cancer Res. 63:4315–4321.
2003.PubMed/NCBI
|
|
15
|
Phillips LM, Zhou X, Cogdell DE, Chua CY,
Huisinga A, R Hess K, Fuller GN and Zhang W: Glioma progression is
mediated by an addiction to aberrant IGFBP2 expression and can be
blocked using anti-IGFBP2 strategies. J Pathol. 239:355–364. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Flyvbjerg A, Mogensen O, Mogensen B and
Nielsen OS: Elevated serum insulin-like growth factor-binding
protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian
cancer: Correlation with cancer antigen 125 and tumor-associated
trypsin inhibitor. J Clin Endocrinol Metab. 82:2308–2313. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee EJ, Mircean C, Shmulevich I, Wang H,
Liu J, Niemistö A, Kavanagh JJ, Lee JH and Zhang W: Insulin-like
growth factor binding protein 2 promotes ovarian cancer cell
invasion. Mol Cancer. 4:72005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Rosen DG, Wang H, Fuller GN, Zhang
W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are
differentially regulated in ovarian cancer of different histologic
types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanety H, Kattan M, Goldberg I, Kopolovic
J, Ravia J, Menczer J and Karasik A: Increased insulin-like growth
factor binding protein-2 (IGFBP-2) gene expression and protein
production lead to high IGFBP-2 content in malignant ovarian cyst
fluid. Br J Cancer. 73:1069–1073. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baron-Hay S, Boyle F, Ferrier A and Scott
C: Elevated serum insulin-like growth factor binding protein-2 as a
prognostic marker in patients with ovarian cancer. Clin Cancer Res.
10:1796–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Russell MR, Graham C, D'Amato A,
Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U,
Jacobs I and Graham RLJ: A combined biomarker panel shows improved
sensitivity for the early detection of ovarian cancer allowing the
identification of the most aggressive type II tumours. Br J Cancer.
117:666–674. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biernacka KM, Uzoh CC, Zeng L, Persad RA,
Bahl A, Gillatt D, Perks CM and Holly JM: Hyperglycaemia-induced
chemoresistance of prostate cancer cells due to IGFBP2. Endocr
Relat Cancer. 20:741–751. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanety H, Madjar Y, Dagan Y, Levi J, Papa
MZ, Pariente C, Goldwasser B and Karasik A: Serum insulin-like
growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3
is decreased in patients with prostate cancer: Correlation with
serum prostate-specific antigen. J Clin Endocrinol Metab.
77:229–233. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cohen P, Peehl DM, Stamey TA, Wilson KF,
Clemmons DR and Rosenfeld RG: Elevated levels of insulin-like
growth factor-binding protein-2 in the serum of prostate cancer
patients. J Clin Endocrinol Metab. 76:1031–1035. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shariat SF, Lamb DJ, Kattan MW, Nguyen C,
Kim J, Beck J, Wheeler TM and Slawin KM: Association of
preoperative plasma levels of insulin-like growth factor I and
insulin-like growth factor binding proteins-2 and −3 with prostate
cancer invasion, progression, and metastasis. J Clin Oncol.
20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kendrick ZW, Firpo MA, Repko RC, Scaife
CL, Adler DG, Boucher KM and Mulvihill SJ: Serum IGFBP2 and MSLN as
diagnostic and prognostic biomarkers for pancreatic cancer. HPB
(Oxford). 16:670–676. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoneyama T, Ohtsuki S, Honda K, Kobayashi
M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T,
et al: Identification of IGFBP2 and IGFBP3 as compensatory
biomarkers for CA19-9 in early-stage pancreatic cancer using a
combination of antibody-based and LC-MS/MS-based proteomics. PLoS
One. 11:e01610092016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Busund LT, Richardsen E, Busund R, Ukkonen
T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of
IGFBP2 in breast cancer compared with benign lesions. J Clin
Pathol. 58:361–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dean SJ, Perks CM, Holly JM, Bhoo-Pathy N,
Looi LM, Mohammed NA, Mun KS, Teo SH, Koobotse MO, Yip CH and
Rhodes A: Loss of PTEN expression is associated with IGFBP2
expression, younger age, and late stage in triple-negative breast
cancer. Am J Clin Pathol. 141:323–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garner CP, Ding YC, John EM, Ingles SA,
Olopade OI, Huo D, Adebamowo C, Ogundiran T and Neuhausen SL:
Genetic variation in IGFBP2 and IGFBP5 is associated with breast
cancer in populations of African descent. Hum Genet. 123:247–255.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang H, Arun BK, Wang H, Fuller GN, Zhang
W, Middleton LP and Sahin AA: IGFBP2 and IGFBP5 overexpression
correlates with the lymph node metastasis in T1 breast carcinomas.
Breast J. 14:261–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Migita T, Narita T, Asaka R, Miyagi E,
Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, et
al: Role of insulin-like growth factor binding protein 2 in lung
adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.
Am J Pathol. 176:1756–1766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo C, Lu H, Gao W, Wang L, Lu K, Wu S,
Pataer A, Huang M, El-Zein R, Lin T, et al: Insulin-like growth
factor binding protein-2 level is increased in blood of lung cancer
patients and associated with poor survival. PLoS One. 8:e749732013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ladd JJ, Busald T, Johnson MM, Zhang Q,
Pitteri SJ, Wang H, Brenner DE, Lampe PD, Kucherlapati R, Feng Z,
et al: Increased plasma levels of the APC-interacting protein
MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer
in women. Cancer Prev Res (Phila). 5:655–664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liou JM, Shun CT, Liang JT, Chiu HM, Chen
MJ, Chen CC, Wang HP, Wu MS and Lin JT: Plasma insulin-like growth
factor-binding protein-2 levels as diagnostic and prognostic
biomarker of colorectal cancer. J Clin Endocrinol Metab.
95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Renehan AG, Jones J, Potten CS, Shalet SM
and O'Dwyer ST: Elevated serum insulin-like growth factor (IGF)-II
and IGF binding protein-2 in patients with colorectal cancer. Br J
Cancer. 83:1344–1350. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang H, Shen SS, Wang H, Diwan AH, Zhang
W, Fuller GN and Prieto VG: Expression of insulin-like growth
factor-binding protein 2 in melanocytic lesions. J Cutan Pathol.
30:599–605. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ranke MB, Maier KP, Schweizer R, Stadler
B, Schleicher S, Elmlinger MW and Flehmig B: Pilot study of
elevated levels of insulin-like growth factor-binding protein-2 as
indicators of hepatocellular carcinoma. Horm Res. 60:174–180.
2003.PubMed/NCBI
|
|
39
|
Zhou Q, Mao YQ, Jiang WD, Chen YR, Huang
RY, Zhou XB, Wang YF, Shi Z, Wang ZS and Huang RP: Development of
IGF signaling antibody arrays for the identification of
hepatocellular carcinoma biomarkers. PLoS One. 7:e468512012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo Q, Yu DY, Yang ZF, Liu DY, Cao HQ and
Liao XW: IGFBP2 upregulates ZEB1 expression and promotes
hepatocellular carcinoma progression through NF-κB signaling
pathway. Dig Liver Dis. 52:573–581. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shi LH, Zhu XQ, Zhao GH, Xia YB and Zhang
YS: Expression of insulin-like growth factor binding protein-2 in
gastric carcinoma and its relationship with cell proliferation.
World J Gastroenterol. 12:6285–6289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang L, Huang W, Chen J, Zhou X, Lu Z and
Zhou H: Expression of IGFBP2 in gastric carcinoma and relationship
with clinicopathologic parameters and cell proliferation. Dig Dis
Sci. 52:248–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tombolan L, Orso F, Guzzardo V, Casara S,
Zin A, Bonora M, Romualdi C, Giorgi C, Bisogno G, Alaggio R, et al:
High IGFBP2 expression correlates with tumor severity in pediatric
rhabdomyosarcoma. Am J Pathol. 179:2611–2624. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vorwerk P, Mohnike K, Wex H, Röhl FW,
Zimmermann M, Blum WF and Mittler U: Insulin-like growth factor
binding protein-2 at diagnosis of childhood acute lymphoblastic
leukemia and the prediction of relapse risk. J Clin Endocrinol
Metab. 90:3022–3027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dawczynski K, Kauf E, Schlenvoigt D, Gruhn
B, Fuchs D and Zintl F: Elevated serum insulin-like growth factor
binding protein-2 is associated with a high relapse risk after
hematopoietic stem cell transplantation in childhood AML. Bone
Marrow Transplant. 37:589–594. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yao X, Sun S, Zhou X, Guo W and Zhang L:
IGF-binding protein 2 is a candidate target of therapeutic
potential in cancer. Tumour Biol. 37:1451–1459. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Holmes KM, Annala M, Chua CY, Dunlap SM,
Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, et al:
Insulin-like growth factor-binding protein 2-driven glioma
progression is prevented by blocking a clinically significant
integrin, integrin-linked kinase, and NF-κB network. Proc Natl Acad
Sci USA. 109:3475–3480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu Y, Li F, Yang YT, Xu XD, Chen JS, Chen
TL, Chen HJ, Zhu YB, Lin JY, Li Y, et al: IGFBP2 promotes
vasculogenic mimicry formation via regulating CD144 and MMP2
expression in glioma. Oncogene. 38:1815–1831. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lin KW, Liao A and Qutub AA: Simulation
predicts IGFBP2-HIF1α interaction drives glioblastoma growth. PLoS
Comput Biol. 11:e10041692015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mehrian-Shai R, Chen CD, Shi T, Horvath S,
Nelson SF, Reichardt JK and Sawyers CL: Insulin growth
factor-binding protein 2 is a candidate biomarker for PTEN status
and PI3K/Akt pathway activation in glioblastoma and prostate
cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Patil SS, Gokulnath P, Bashir M, Shwetha
SD, Jaiswal J, Shastry AH, Arimappamagan A, Santosh V and Kondaiah
P: Insulin-like growth factor binding protein-2 regulates β-catenin
signaling pathway in glioma cells and contributes to poor patient
prognosis. Neuro Oncol. 18:1487–1497. 2016.PubMed/NCBI
|
|
52
|
Han S, Li Z, Master LM, Master ZW and Wu
A: Exogenous IGFBP-2 promotes proliferation, invasion, and
chemoresistance to temozolomide in glioma cells via the integrin
β1-ERK pathway. Br J Cancer. 111:1400–1409. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Moore MG, Wetterau LA, Francis MJ, Peehl
DM and Cohen P: Novel stimulatory role for insulin-like growth
factor binding protein-2 in prostate cancer cells. Int J Cancer.
105:14–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Uzoh CC, Holly JM, Biernacka KM, Persad
RA, Bahl A, Gillatt D and Perks CM: Insulin-like growth
factor-binding protein-2 promotes prostate cancer cell growth via
IGF-dependent or -independent mechanisms and reduces the efficacy
of docetaxel. Br J Cancer. 104:1587–1593. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sehgal P, Kumar N, Praveen Kumar VR, Patil
S, Bhattacharya A, Vijaya Kumar M, Mukherjee G and Kondaiah P:
Regulation of protumorigenic pathways by insulin like growth factor
binding protein2 and its association along with β-catenin in breast
cancer lymph node metastasis. Mol Cancer. 12:632013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Perks CM, Vernon EG, Rosendahl AH, Tonge D
and Holly JM: IGF-II and IGFBP-2 differentially regulate PTEN in
human breast cancer cells. Oncogene. 26:5966–5972. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chakrabarty S and Kondratick L:
Insulin-like growth factor binding protein-2 stimulates
proliferation and activates multiple cascades of the
mitogen-activated protein kinase pathways in NIH-OVCAR3 human
epithelial ovarian cancer cells. Cancer Biol Ther. 5:189–197. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lu H, Wang L, Gao W, Meng J, Dai B, Wu S,
Minna J, Roth JA, Hofstetter WL, Swisher SG and Fang B: IGFBP2/FAK
pathway is causally associated with dasatinib resistance in
non-small cell lung cancer cells. Mol Cancer Ther. 12:2864–2873.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ben-Shmuel A, Shvab A, Gavert N, Brabletz
T and Ben-Ze'ev A: Global analysis of L1-transcriptomes identified
IGFBP-2 as a target of ezrin and NF-κB signaling that promotes
colon cancer progression. Oncogene. 32:3220–3230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou Z, Lu H, Zhu S, Gomaa A, Chen Z, Yan
J, Washington K, El-Rifai W, Dang C and Peng D: Activation of
EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma
cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer
Res. 38:132019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen X, Zheng J, Zou Y, Song C, Hu X and
Zhang CC: IGF binding protein 2 is a cell-autonomous factor
supporting survival and migration of acute leukemia cells. J
Hematol Oncol. 6:722013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li T, Zhang C, Zhao G, Zhang X, Hao M,
Hassan S, Zhang M, Zheng H, Yang D, Liu L, et al: IGFBP2 regulates
PD-L1 expression by activating the EGFR-STAT3 signaling pathway in
malignant melanoma. Cancer Lett. 477:19–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Das SK, Bhutia SK, Azab B, Kegelman TP,
Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, et
al: MDA-9/syntenin and IGFBP-2 promote angiogenesis in human
melanoma. Cancer Res. 73:844–854. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yao X, Wang Y, Duan Y, Zhang Q, Li P, Jin
R, Tao Y, Zhang W, Wang X, Jing C and Zhou X: IGFBP2 promotes
salivary adenoid cystic carcinoma metastasis by activating the
NF-κB/ZEB1 signaling pathway. Cancer Lett. 432:38–46. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Maier HJ, Schmidt-Strassburger U, Huber
MA, Wiedemann EM, Beug H and Wirth T: NF-kappaB promotes
epithelial-mesenchymal transition, migration and invasion of
pancreatic carcinoma cells. Cancer Lett. 295:214–228. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Azar WJ, Azar SH, Higgins S, Hu JF,
Hoffman AR, Newgreen DF, Werther GA and Russo VC: IGFBP-2 enhances
VEGF gene promoter activity and consequent promotion of
angiogenesis by neuroblastoma cells. Endocrinology. 152:3332–3342.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Png KJ, Halberg N, Yoshida M and Tavazoie
SF: A microRNA regulon that mediates endothelial recruitment and
metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Godard S, Getz G, Delorenzi M, Farmer P,
Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF,
Dietrich PY, et al: Classification of human astrocytic gliomas on
the basis of gene expression: A correlated group of genes with
angiogenic activity emerges as a strong predictor of subtypes.
Cancer Res. 63:6613–6625. 2003.PubMed/NCBI
|
|
71
|
Azar WJ, Zivkovic S, Werther GA and Russo
VC: IGFBP-2 nuclear translocation is mediated by a functional NLS
sequence and is essential for its pro-tumorigenic actions in cancer
cells. Oncogene. 33:578–588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Maniotis AJ, Folberg R, Hess A, Seftor EA,
Gardner LM, Pe'er J, Trent JM, Meltzer PS and Hendrix MJ: Vascular
channel formation by human melanoma cells in vivo and in vitro:
Vasculogenic mimicry. Am J Pathol. 155:739–752. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer
PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and
Hendrix MJ: Cooperative interactions of laminin 5 gamma2 chain,
matrix metalloproteinase-2, and membrane
type-1-matrix/metalloproteinase are required for mimicry of
embryonic vasculogenesis by aggressive melanoma. Cancer Res.
61:6322–6327. 2001.PubMed/NCBI
|
|
74
|
Park KH, Gad E, Goodell V, Dang Y, Wild T,
Higgins D, Fintak P, Childs J, Dela Rosa C and Disis ML:
Insulin-like growth factor-binding protein-2 is a target for the
immunomodulation of breast cancer. Cancer Res. 68:8400–8409. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cai J, Chen Q, Cui Y, Dong J, Chen M, Wu P
and Jiang C: Immune heterogeneity and clinicopathologic
characterization of IGFBP2 in 2447 glioma samples. OncoImmunology.
7:e14265162018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li Y, Jiang T, Zhang J, Zhang B, Yang W,
You G, Xu K, Wu J, Luo C and Song SW: Elevated serum antibodies
against insulin-like growth factor-binding protein-2 allow
detecting early-stage cancers: Evidences from glioma and colorectal
carcinoma studies. Ann Oncol. 23:2415–2422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhai H, Heppner FL and Tsirka SE:
Microglia/macrophages promote glioma progression. Glia. 59:472–485.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chesik D, De Keyser J and Wilczak N:
Involvement of insulin-like growth factor binding protein-2 in
activated microglia as assessed in post mortem human brain.
Neurosci Lett. 362:14–16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Elmlinger MW, Deininger MH, Schuett BS,
Meyermann R, Duffner F, Grote EH and Ranke MB: In vivo expression
of insulin-like growth factor-binding protein-2 in human gliomas
increases with the tumor grade. Endocrinology. 142:1652–1658. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Firth SM and Baxter RC: Cellular actions
of the insulin-like growth factor binding proteins. Endocr Rev.
23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Pereira JJ, Meyer T, Docherty SE, Reid HH,
Marshall J, Thompson EW, Rossjohn J and Price JT: Bimolecular
interaction of insulin-like growth factor (IGF) binding protein-2
with alphavbeta3 negatively modulates IGF-I-mediated migration and
tumor growth. Cancer Res. 64:977–984. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hoeflich A, Nedbal S, Blum WF, Erhard M,
Lahm H, Brem G, Kolb HJ, Wanke R and Wolf E: Growth inhibition in
giant growth hormone transgenic mice by overexpression of
insulin-like growth factor-binding protein-2. Endocrinology.
142:1889–1898. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Conover CA: Insulin-like growth
factor-binding proteins and bone metabolism. Am J Physiol
Endocrinol Metab. 294:E10–E14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lund J, Søndergaard MT, Conover CA and
Overgaard MT: Heparin-binding mechanism of the IGF2/IGF-binding
protein 2 complex. J Mol Endocrinol. 52:345–355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Šunderić M, Đukanović B, Malenković V and
Nedić O: Molecular forms of the insulin-like growth factor-binding
protein-2 in patients with colorectal cancer. Exp Mol Pathol.
96:48–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Miyamoto S, Nakamura M, Yano K, Ishii G,
Hasebe T, Endoh Y, Sangai T, Maeda H, Shi-Chuang Z, Chiba T and
Ochiai A: Matrix metalloproteinase-7 triggers the matricrine action
of insulin-like growth factor-II via proteinase activity on
insulin-like growth factor binding protein 2 in the extracellular
matrix. Cancer Sci. 98:685–691. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rorive S, Berton A, D'Haene N, Takacs CN,
Debeir O, Decaestecker C and Salmon I: Matrix metalloproteinase-9
interplays with the IGFBP2-IGFII complex to promote cell growth and
motility in astrocytomas. Glia. 56:1679–1690. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shen X, Xi G, Maile LA, Wai C, Rosen CJ
and Clemmons DR: Insulin-like growth factor (IGF) binding protein 2
functions coordinately with receptor protein tyrosine phosphatase β
and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol
Cell Biol. 32:4116–4130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Russo VC, Schütt BS, Andaloro E, Ymer SI,
Hoeflich A, Ranke MB, Bach LA and Werther GA: Insulin-like growth
factor binding protein-2 binding to extracellular matrix plays a
critical role in neuroblastoma cell proliferation, migration, and
invasion. Endocrinology. 146:4445–4455. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang GK, Hu L, Fuller GN and Zhang W: An
interaction between insulin-like growth factor-binding protein 2
(IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell
mobility. J Biol Chem. 281:14085–14091. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Schütt BS, Langkamp M, Rauschnabel U,
Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like
growth factor binding protein-2 in tumor cells. J Mol Endocrinol.
32:859–868. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Mendes KN, Wang GK, Fuller GN and Zhang W:
JNK mediates insulin-like growth factor binding protein 2/integrin
alpha5-dependent glioma cell migration. Int J Oncol. 37:143–153.
2010.PubMed/NCBI
|
|
93
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT pathway in vivo, cancer mouse models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Levitt RJ, Georgescu MM and Pollak M:
PTEN-induction in U251 glioma cells decreases the expression of
insulin-like growth factor binding protein-2. Biochem Biophys Res
Commun. 336:1056–1061. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Scrideli CA, Carlotti CG Jr, Mata JF,
Neder L, Machado HR, Oba-Sinjo SM, Rosemberg S, Marie SK and Tone
LG: Prognostic significance of co-overexpression of the
EGFR/IGFBP-2/HIF-2A genes in astrocytomas. J Neurooncol.
83:233–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Villani RM, Adolphe C, Palmer J, Waters MJ
and Wainwright BJ: Patched1 inhibits epidermal progenitor cell
expansion and basal cell carcinoma formation by limiting Igfbp2
activity. Cancer Prev Res (Phila). 3:1222–1234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Foulstone EJ, Zeng L, Perks CM and Holly
JM: Insulin-like growth factor binding protein 2 (IGFBP-2) promotes
growth and survival of breast epithelial cells: Novel regulation of
the estrogen receptor. Endocrinology. 154:1780–1793. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yuan Q, Cai HQ, Zhong Y, Zhang MJ, Cheng
ZJ, Hao JJ, Wang MR and Wan JH: Overexpression of IGFBP2 mRNA
predicts poor survival in patients with glioblastoma. Biosci Rep.
39:BSR201900452019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Han S, Meng L, Han S, Wang Y and Wu A:
Plasma IGFBP-2 levels after postoperative combined radiotherapy and
chemotherapy predict prognosis in elderly glioblastoma patients.
PLoS One. 9:e937912014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Gállego Pérez-Larraya J, Paris S, Idbaih
A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K,
Marie Y, Sanson M, et al: Diagnostic and prognostic value of
preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in
patients with glioblastoma. Cancer. 120:3972–3980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
So AI, Levitt RJ, Eigl B, Fazli L,
Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M and Pollak M:
Insulin-like growth factor binding protein-2 is a novel therapeutic
target associated with breast cancer. Clin Cancer Res.
14:6944–6954. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kalledsøe L, Dragsted LO, Hansen L, Kyrø
C, Grønbæk H, Tjønneland A and Olsen A: The insulin-like growth
factor family and breast cancer prognosis: A prospective cohort
study among postmenopausal women in Denmark. Growth Horm IGF Res.
44:33–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sohn J, Do KA, Liu S, Chen H, Mills GB,
Hortobagyi GN, Meric-Bernstam F and Gonzalez-Angulo AM: Functional
proteomics characterization of residual triple-negative breast
cancer after standard neoadjuvant chemotherapy. Ann Oncol.
24:2522–2526. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Probst-Hensch NM, Steiner JH, Schraml P,
Varga Z, Zürrer-Härdi U, Storz M, Korol D, Fehr MK, Fink D,
Pestalozzi BC, et al: IGFBP2 and IGFBP3 protein expressions in
human breast cancer: Association with hormonal factors and obesity.
Clin Cancer Res. 16:1025–1032. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Richardsen E, Ukkonen T, Bjørnsen T,
Mortensen E, Egevad L and Busch C: Overexpression of IGBFB2 is a
marker for malignant transformation in prostate epithelium.
Virchows Arch. 442:329–335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Mita K, Nakahara M and Usui T: Expression
of the insulin-like growth factor system and cancer progression in
hormone-treated prostate cancer patients. Int J Urol. 7:321–329.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lancaster JM, Sayer RA, Blanchette C,
Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW,
Marks JR and Berchuck A: High expression of insulin-like growth
factor binding protein-2 messenger RNA in epithelial ovarian
cancers produces elevated preoperative serum levels. Int J Gynecol
Cancer. 16:1529–1535. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu
KF and Chou CY: Circulating IGF system and treatment outcome in
epithelial ovarian cancer. Endocr Relat Cancer. 21:217–229. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Zhang Y, Ying X, Han S, Wang J, Zhou X,
Bai E, Zhang J and Zhu Q: Autoantibodies against insulin-like
growth factorbinding protein-2 as a serological biomarker in the
diagnosis of lung cancer. Int J Oncol. 42:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hur H, Yu EJ, Ham IH, Jin HJ and Lee D:
Preoperative serum levels of insulin-like growth factor-binding
protein 2 predict prognosis of gastric cancer patients. Oncotarget.
8:10994–11003. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Warnecke-Eberz U, Metzger R, Holscher AH,
Drebber U and Bollschweiler E: Diagnostic marker signature for
esophageal cancer from transcriptome analysis. Tumour Biol.
37:6349–6358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Myers AL, Lin L, Nancarrow DJ, Wang Z,
Ferrer-Torres D, Thomas DG, Orringer MB, Lin J, Reddy RM, Beer DG
and Chang AC: IGFBP2 modulates the chemoresistant phenotype in
esophageal adenocarcinoma. Oncotarget. 6:25897–25916. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang W, Wang H, Song SW and Fuller GN:
Insulin-like growth factor binding protein 2: Gene expression
microarrays and the hypothesis-generation paradigm. Brain Pathol.
12:87–94. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Juncker-Jensen A, Lykkesfeldt AE, Worm J,
Ralfkiaer U, Espelund U and Jepsen JS: Insulin-like growth factor
binding protein 2 is a marker for antiestrogen resistant human
breast cancer cell lines but is not a major growth regulator.
Growth Horm IGF Res. 16:224–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Neuhouser ML, Platz EA, Till C, Tangen CM,
Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, et al:
Insulin-like growth factors and insulin-like growth factor-binding
proteins and prostate cancer risk: Results from the prostate cancer
prevention trial. Cancer Prev Res (Phila). 6:91–99. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Tennant MK, Thrasher JB, Twomey PA,
Birnbaum RS and Plymate SR: Insulin-like growth factor-binding
protein-2 and −3 expression in benign human prostate epithelium,
prostate intraepithelial neoplasia, and adenocarcinoma of the
prostate. J Clin Endocrinol Metab. 81:411–420. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Bubendorf L, Kolmer M, Kononen J, Koivisto
P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, et
al: Hormone therapy failure in human prostate cancer: Analysis by
complementary DNA and tissue microarrays. J Natl Cancer Inst.
91:1758–1764. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Karasik A, Menczer J, Pariente C and
Kanety H: Insulin-like growth factor-I (IGF-I) and IGF-binding
protein-2 are increased in cyst fluids of epithelial ovarian
cancer. J Clin Endocrinol Metab. 78:271–276. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yee D, Morales FR, Hamilton TC and Von
Hoff DD: Expression of insulin-like growth factor I, its binding
proteins, and its receptor in ovarian cancer. Cancer Res.
51:5107–5112. 1991.PubMed/NCBI
|
|
120
|
Hu Q, Huang L, Kuang X, Zhang H, Ling G,
Chen X, Li K, Deng Z and Zhou J: Is insulin-like growth factor
binding protein 2 associated with metastasis in lung cancer? Clin
Exp Metastasis. 31:535–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang J, Hu ZG, Li D, Xu JX and Zeng ZG:
Gene expression and prognosis of insulin-like growth factor-binding
protein family members in non-small cell lung cancer. Oncol Rep.
42:1981–1995. 2019.PubMed/NCBI
|
|
122
|
Yazawa T, Sato H, Shimoyamada H, Okudela
K, Woo T, Tajiri M, Ogura T, Ogawa N, Suzuki T, Mitsui H, et al:
Neuroendocrine cancer-specific up-regulating mechanism of
insulin-like growth factor binding protein-2 in small cell lung
cancer. Am J Pathol. 175:976–987. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Pickard A and McCance DJ: IGF-Binding
Protein 2 - Oncogene or tumor suppressor? Front Endocrinol
(Lausanne). 6:252015. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Chen R, Brentnall TA, Pan S, Cooke K,
Moyes KW, Lane Z, Crispin DA, Goodlett DR, Aebersold R and Bronner
MP: Quantitative proteomics analysis reveals that proteins
differentially expressed in chronic pancreatitis are also
frequently involved in pancreatic cancer. Mol Cell Proteomics.
6:1331–1342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yi HK, Hwang PH, Yang DH, Kang CW and Lee
DY: Expression of the insulin-like growth factors (IGFs) and the
IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J
Cancer. 37:2257–2263. 2001. View Article : Google Scholar : PubMed/NCBI
|
